Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
J Health Econ ; 20(6): 1089-96, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11758050

RESUMO

Using detailed panel data on local alcohol policy changes in Texas, this paper tests whether the effect of these changes on alcohol-related accidents depends on whether the policy change involves where the alcohol is consumed and the type of alcohol consumed. After controlling for both county and year fixed effects, we find evidence that: (i) the sale of beer and wine may actually decrease expected accidents; and (ii) the sale of higher alcohol-content liquor may present greater risk to highway safety than the sale of just beer and wine.


Assuntos
Acidentes de Trânsito/prevenção & controle , Consumo de Bebidas Alcoólicas/legislação & jurisprudência , Bebidas Alcoólicas/provisão & distribuição , Comércio/legislação & jurisprudência , Política Pública , Acidentes de Trânsito/estatística & dados numéricos , Bebidas Alcoólicas/classificação , Bebidas Alcoólicas/economia , Comércio/economia , Humanos , Governo Local , Texas/epidemiologia , Viagem
2.
Evid Based Preclin Med ; 1(1): e00006, 2014 12.
Artigo em Inglês | MEDLINE | ID: mdl-27668084

RESUMO

BACKGROUND: The development of therapeutics is often characterized by promising animal research that fails to translate into clinical efficacy; this holds for the development of gene therapy in glioma. We tested the hypothesis that this is because of limitations in the internal and external validity of studies reporting the use of gene therapy in experimental glioma. METHOD: We systematically identified studies testing gene therapy in rodent glioma models by searching three online databases. The number of animals treated and median survival were extracted and studies graded using a quality checklist. We calculated median survival ratios and used random effects meta-analysis to estimate efficacy. We explored effects of study design and quality and searched for evidence of publication bias. RESULTS: We identified 193 publications using gene therapy in experimental glioma, including 6,366 animals. Overall, gene therapy improved median survival by a factor of 1.60 (95% CI 1.53-1.67). Study quality was low and the type of gene therapy did not account for differences in outcome. Study design characteristics accounted for a significant proportion of between-study heterogeneity. We observed similar findings in a data subset limited to the most common gene therapy. CONCLUSION: As the dysregulation of key molecular pathways is characteristic of gliomas, gene therapy remains a promising treatment for glioma. Nevertheless, we have identified areas for improvement in conduct and reporting of studies, and we provide a basis for sample size calculations. Further work should focus on genes of interest in paradigms recapitulating human disease. This might improve the translation of such therapies into the clinic.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA